(Toronto Stock Exchange:TST)
Transforming the Bladder Cancer Treatment Landscape
Focus on MCNA Approval & LaunchThis presentation contains forward-looking statements about Telesta Therapeutics' business objectives, strategies and outlooks that involve risks and uncertainties. These statements are 'forward- looking' because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward- looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. A detailed description of the risks that could cause actual events or results to materially differ from our current expectations can be found in our public filings available at www.sedar.com. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
2
Focused on MCNA - a biologic therapeutic for 2nd line treatment of high risk refractory/relapsing non-muscle invasive bladder cancer
Significant unmet medical need
Submitted Biologics License Application (BLA) with FDA on June 30, 2015
Designated for Priority Review - August 27, 2015
Advisory Committee (AdComm) meeting - November 18, 2015
PDUFA date - February 27, 2016
Building a targeted U.S. commercial infrastructure
Global (ex-U.S., ex-Japan) license with Ipsen on October 28,
2015
Seeking Japanese partner
Fully funded business plan
Non-Confidential 3
Leadership TeamDr. Michael Berendt
CEO & Chief Scientist
Senior Executive Roles: Pharma (Bayer, Pfizer), Venture Capital (AEA, RCT) Biotech (Aegera Therapeutics); Boards: Waters Corp (NYSE:WAT), Anchor Therapeutics (Chair), Alethia Biotherapeutics (Chair), Neomed Institute
Donald Olds
Chief Operating Officer
Senior Executive Roles: Biotech (Aegera Therapeutics), IT, Telecom, Investment Banking (TD Securities); Boards: Neomed Institute (Chair), Oxfam Quebec (Chair)
Brian Ford
Chief Financial Officer
Senior Executive Roles - Finance & Consulting: Ernst & Young (EY)
Monique Champagne Vice President, Clinical Research
Leadership Roles: Clinical Research & Development - Biotech, CROs, Pharma: Xanthus, Supratek, Quintiles, Wyeth- Ayerst, Scat
Dr. Mathieu Boudreau Vice President, Corporate Development & Licensing
Leadership Roles, Corporate/Business Development - Specialty Pharma & Biotech: Pendopharm, Pharmascience, Aegera Therapeutics
Brian Groch
Chief Commercial Officer
Leadership Roles: Commercial Operations, Market Access, Marketing
& Sales - Specialty Pharma/ Pharma:
Horizon Pharma, Exsto, Dendreon, Novartis, Merck & Co.
Non-Confidential 4
distributed by |